Preclinical multimodality phantom design for quality assurance of tumor size measurement

BMC Medical Physics

Volumn 11, Issue 1, 2011, Pages

  Lee, Yongsook C ^a   Fullerton, Gary D ^b   Baiu, Cristel ^c   Lescrenier, Margaret G ^c   Goins, Beth A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Gammex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053357741     PISSN: None     EISSN: 17566649     Source Type: Journal    
DOI: 10.1186/1756-6649-11-1     Document Type: Article

References (28)

1. Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Boden K, Eriksson-Alm Y, Berg E, Fujii H, Kubo A, Blomqvist L. Radiologic measurements of tumor response to treatment: Practical approaches and limitations. RadioGraphics 2008, 28:329-344. 10.1148/rg.282075068, 18349443.
2. US Food and Drug Administration Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics 2007, (accessed September 17, 2011), US Food and Drug Administration., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
3. O'Connor JPB, Jackson A, Asselin M, Buckley DL, Parker GJM, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008, 9:766-776. 10.1016/S1470-2045(08)70196-7, 18672212.
4. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50:122S-150S. 10.2967/jnumed.108.057307, 2755245, 19403881.
5. World Health Organization (WHO) WHO handbook for reporting results of cancer treatment 1979, Geneva, Switzerland: WHO Offset Publication, World Health Organization (WHO).
6. Saini S. Radiologic measurement of tumor size in clinical trials: Past, present, and future. AJR 2001, 176:333-334.
7. Cortes J, Rodriguez J, Diaz-Gonzalez JA, Garzon C, Gurpide A, Arbea L, Gill-Bazo I, Navarro V, Cambeiro M, Nicolas AI, Martin-Algarra S, Garcia-Foncillas J, Calvo E. Comparison of unidimensional and bidimensional measurement in metastatic non-small cell lung cancer. Br J Cancer 2002, 87:158-160. 10.1038/sj.bjc.6600449, 2376101, 12107835.
8. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: Comparison of unidimensional, bidimensional, and volumetric techniques-Initial observations. Radiology 2002, 225:416-419. 10.1148/radiol.2252011604, 12409574.
9. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im Y, Kang WK, Lee MH, Lee KS, Park K. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003, 33:533-537. 10.1093/jjco/hyg093, 14623923.
10. Therasse P, Eisenhauer PA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006, 42:1031-1039. 10.1016/j.ejca.2006.01.026, 16616487.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
12. Verweij J, Therasse P, Eisenhauer E, . on behalf of RECIST working group Cancer clinical trial outcomes: Any progress in tumor-size assessment?. Eur J Cancer 2009, 45:225-227. 10.1016/j.ejca.2008.10.025, 19068275, on behalf of RECIST working group.
13. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001, 51:56-61.
14. Jensen MM, Joergensen JT, Binderup T, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008, 8:16. 10.1186/1471-2342-8-16, 2575188, 18925932.
15. Breiman RS, Beck JW, Korobkin M, Glenny R, Heaston DK, Moore AV, Ram PC. Volume determinations using computed tomography. AJR 1982, 138:329-333.
16. Disler D, Marr D, Rosenthal D. Accuracy of volume measurements of computed tomography and magnetic resonance imaging phantoms by three-dimensional reconstruction and preliminary clinical application. Invest Radiol 1994, 29:739-745. 10.1097/00004424-199408000-00002, 7960623.
17. Van Hoe L, Haven F, Bellon E, Baert AL, Bosmans H, Feron M, Suetens P, Marchal G. Factors influencing the accuracy of volume measurements in spiral CT: A phantom study. J Comput Assist Tomogr 1997, 21:332-338. 10.1097/00004728-199703000-00034, 9071313.
18. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RTD, Reznek RH. CT assessment of tumor response to treatment: Comparison of linear, cross-sectional and volumetric measures of tumor size. Br J Radiol 2000, 73:1178-1184.
19. Keil S, Plumhans C, Behrendt FF, Stanzel S, Suehling M, Muhlenbruch G, Mahnken AH, Gunther RW, Das M. Automated measurement of lymph nodes: A phantom study. Eur Radiol 2009, 19:1079-1086. 10.1007/s00330-008-1254-9, 19107487.
20. Keil S, Plumhans C, Behrendt FF, Stanzel S, Suehling M, Muhlenbruch G, Mahnken AH, Gunther RW, Das M. Semi-automated quantification of hepatic lesions in a phantom. Invest Radiol 2009, 44:82-88. 10.1097/RLI.0b013e3181911ffa, 19104439.
21. Fabel M, Biederer J, Jochens A, Bornemann L, Soza G, Heller M, Bolte H. Semi-automated volumetric analysis of artificial lymph nodes in a phantom study. Eur J Radiol 2010,
22. Lindner U, Lawrentschuk N, Weersink RA, Raz O, Hlasny E, Sussman MS, Davidson SR, Gertner MR, Trachtenberg J. Construction and evaluation of an anatomically correct multi-image modality compatible phantom for prostate cancer focal ablation. J Urol 2010, 184:352-357. 10.1016/j.juro.2010.03.001, 20488477.
23. Pomper MG. Can small animal imaging accelerate drug development?. J Cell Biochem Suppl 2002, 39:211-220.
24. Weissleder R. Scaling down imaging: Molecular mapping of cancer in mice. Nat Rev Cancer 2002, 2:11-18. 10.1038/nrc701, 11902581.
25. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006, 12:5277-5287. 10.1158/1078-0432.CCR-06-0436, 17000660.
26. Ollivier L, Leclère J, Thiesse P, Stefano DD, Vincent C. Measurement of tumour response to cancer treatment: morphologic imaging role. Bull Cancer 2007, 94:171-177.
27. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-154. 10.1007/BF00300234, 2544306.
28. D'Souza WD, Madsen EL, Unal O, Vigen KK, Frank GR, Thomadsen BR. Tissue mimicking materials for a multi-imaging modality prostate phantom. Med Phys 2001, 28:688-700. 10.1118/1.1354998, 11339767.